Trial Profile

A Phase 2 Evaluation of Daratumumab-Based Treatment in Newly Diagnosed Multiple Myeloma Patients With Renal Insufficiency

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 15 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Thalidomide (Primary)
Indications Acute kidney injury; Multiple myeloma; Renal failure
Focus Therapeutic Use

Most Recent Events

01 Jul 2024 Status changed from recruiting to discontinued due to slow accrual.
06 Jun 2023 Results (n=13) assessing efficacy and safety of daratumumab-based induction therapy in patients with multiple myeloma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
21 Apr 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com